Introduction Antipsychotic medications are mainstays in the treatment of schizophrenia and
a range of other psychotic disorders. Sources of data Recent meta-analyses of antipsychotic …

Objective: To determine effects of physical activity on depressive symptoms (primary
objective), symptoms of schizophrenia, anthropometric measures, aerobic capacity, and …

The prognosis of diabetic ketoacidosis has undergone incredibly remarkable evolution since
the discovery of insulin nearly a century ago. The incidence and economic burden of …

The lifespan of people with severe mental illness (SMI) is shorter compared to the general
population. This excess mortality is mainly due to physical illness. We report prevalence …

Antipsychotic medications can induce cardiovascular and metabolic abnormalities (such as
obesity, hyperglycemia, dyslipidemia and the metabolic syndrome) that are associated with …

Background: Sodium–glucose cotransporter-2 (SGLT-2) inhibitors could increase the risk for
diabetic ketoacidosis (DKA). Objective: To assess whether SGLT-2 inhibitors, compared with …

Abstract The American Medical Association recently recognized obesity as both an illness
and a leading cause of preventable death and chronic disease. This association is not only …

These updated guidelines are based on a first edition of the World Federation of Societies of
Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in …

N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine (PCP),
dizocilpine (MK-801) and ketamine have long been considered a model of schizophrenia …

Physical disorders are, compared to the general population, more prevalent in people with
severe mental illness (SMI). Although this excess morbidity and mortality is largely due to …